dothelial cells are a major source of endothelin (ET)-1, but the possibility that vascular adventitial fibroblasts generate ET-1 has not been explored. We hypothesized that aortic adventitial fibroblasts have the ability to produce ET-1, which may contribute to extracellular matrix synthesis. Vascular adventitial fibroblasts were isolated from mouse aorta and incubated with various concentrations of angiotensin II (ANG II). mRNA levels of preproET-1 and type I procollagen were detected with relative RT-PCR. ET-1 levels in culture medium were measured with ELISA. Protein levels of procollagen were detected with Western blotting. ANG II (10 and 100 nM, 1 M) induced a time-and concentration-dependent increase in preproET-1 mRNA levels (P Ͻ 0.05). Induction of preproET-1 mRNA was accompanied by release of immunoreactive peptide ET-1 (P Ͻ 0.05). ANG II-evoked increases in preproET-1 mRNA expression and ET-1 release were blocked by losartan (100 M), an AT1 receptor antagonist, but not PD-123319 (100 M), an AT2 receptor antagonist. To further confirm our findings, we cloned and then sequenced vascular fibroblast preproET-1 bidirectionally with T7 and M13 reverse sequencing primers. Their nucleotide sequences were identical to preproET-1 cDNA from mouse vascular endothelial cells (accession no. AB081657). Moreover, ANG II-induced type I procollagen mRNA and protein expression were inhibited by BQ-123 (10 M), an ETA receptor inhibitor, but not BQ-788 (10 M), an ETB receptor inhibitor, suggesting a significant role of adventitial ET-1 in regulation of extracellular matrix synthesis. The results demonstrate that vascular adventitial fibroblasts are able to synthesize and release ET-1 in response to ANG II. adventitia; fibroblast; angiotensin II; collagen; procollagen IN CONTRAST TO THE ACCEPTED ROLE of the vascular endothelium in the regulation of vascular smooth muscle function, the role of the adventitia in the regulation of vascular smooth muscle function is largely unexplored. Recently, the contribution of adventitial fibroblasts to neointima formation and vascular remodeling has received considerable attention (24, 34, 34, 36, 39, 49) . Moreover, we and others have demonstrated that the adventitia is the primary site of superoxide anion generation in the mouse (45, 46), rat (28, 47, 48) , and rabbit aorta (28). Indeed, investigators in our group discovered that generation of superoxide anion from NADPH oxidase contributes to angiotensin II (ANG II) evoked hypertension and that adventitial NADPH oxidase appears to contribute to this effect of ANG II (45, 46) .
IN CONTRAST TO THE ACCEPTED ROLE of the vascular endothelium in the regulation of vascular smooth muscle function, the role of the adventitia in the regulation of vascular smooth muscle function is largely unexplored. Recently, the contribution of adventitial fibroblasts to neointima formation and vascular remodeling has received considerable attention (24, 34, 34, 36, 39, 49) . Moreover, we and others have demonstrated that the adventitia is the primary site of superoxide anion generation in the mouse (45, 46) , rat (28, 47, 48) , and rabbit aorta (28) . Indeed, investigators in our group discovered that generation of superoxide anion from NADPH oxidase contributes to angiotensin II (ANG II) evoked hypertension and that adventitial NADPH oxidase appears to contribute to this effect of ANG II (45, 46) .
The role of ANG II in hypertension is well established. Certain types of hypertension are associated with elevated circulating levels of ANG II. On the other hand, local production of ANG II in the vessel wall may have autocrine and paracrine effects, even though the circulating peptide level is normal or low (23) . By activating ANG II type 1 (AT 1 ) receptors, ANG II may exert its effects on the vasculature either directly, through activation of phospholipase C, or indirectly, through the endothelin system. Indeed, several studies indicate that endothelin (ET)-1 may contribute to the vascular actions of ANG II (3, 7, 8, 12, 21, 26) . In addition, overexpression of ET-1 has been found in some models of hypertension, including the ANG II-infused hypertensive rat (11, 30) .
ET-1 is a 21-amino acid peptide containing two disulfide bridges. It is the most potent endogenous vasoconstrictor (2, 35) , as well as a potent mitogenic agent (17, 22) . The most abundant source of ET-1 in vivo under physiological conditions is vascular endothelium (19, 51) . The effects of ET-1 are mediated by endothelin type A (ET A ) and endothelin type B (ET B ) receptors (33) . ET-1 synthesis also has been reported in nonendothelial cells, including vascular smooth muscle cells (16, 18, 41) , cardiomyocytes (1, 32) , and cardiac fibroblasts (9, 10, 15) . However, the possibility that the adventitia of the vasculature might generate ET-1 has not been studied.
Both ANG II (14, 43) and ET-1 (42) have been reported to stimulate vascular collagen synthesis. Accumulation of interstitial collagen is frequently associated with vascular disease (20, 29) . Although vascular collagen production is regulated by many factors, studies of renal vascular fibrosis have suggested that ET-1 also could contribute to ANG II-evoked collagen expression in the renal vasculature (6) . However, the possibility that the ANG II-evoked collagen expression may occur at the level of the vascular adventitia has not been reported.
In view of these considerations, we sought to determine whether the adventitia of the vasculature is capable of generating ET-1 in response to ANG II and to determine whether such an event is biologically relevant. In the present study, we demonstrated that ANG II is able to induce ET-1 release from vascular adventitial fibroblasts. Using reverse transcriptasepolymerase change reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), we compared ET-1 synthesis and release from cultured aortic adventitial fibroblasts in the presence and absence of ANG II. We further demonstrated that this induction of ET-1 is mediated by AT I receptors. Finally, we determined whether ET-1 release from adventitial fibroblasts exerts a biologically meaningful effect by examining its role in ANG II-induced collagen expression. anesthetized with inhaled isoflurane and then killed by vertebral dislocation. Thoracic aortas were removed and cleaned under sterile conditions. The media was separated from the adventitia. The adventitia was rinsed three times with culture medium. The isolated adventitia was then cut into 1-to 2-mm 2 flat segments and planted on 0.1% gelatin-coated dishes. Fresh medium consisting of Dulbecco's modified Eagle's medium and F-12 nutrient mixture (DMEM/F-12) supplemented with 10% FCS (GIBCO, Grand Island, NY), 20 mM HEPES (Boehringer Mannheim), 2 mM L-glutamine, 50 UI/ml penicillin, and 50 g/ml streptomycin (Sigma, Oakville, ON, Canada) was added into each well. The explants were incubated in a humidified incubator at 37°C in a 95% air-5% CO 2 atmosphere until the cells reached confluence, typically 7-12 days. From the fourth day onward, the culture medium was removed and replaced with fresh medium every 48 h. Confluent cells were subsequently harvested for passage with a trypsin (0.05%) and EDTA (0.02%) solution (Sigma). When cells from passage 1 or 2 had reached 80% confluency, they were frozen and kept at Ϫ70°C until further use.
Subcultures for up to three passages were used in our experiments. To examine whether there were changes in cell responses or morphology among the different passages, we examined the cell shapes, preproET-1 mRNA, and ET-1 peptide responses (n ϭ 2-4) to ANG II in the cells from passage 1 to passage 4. The responses are consistent among the cells from passages 1-4 when the cell passage ratio was 1:3 (data not shown). Cells were grown to confluence and incubated in serum-free medium for 24 h. Cells were treated with ANG II at 1, 10, and 100 nM for 0.5, 1, 1.5, 3, 6, 12, or 24 h. The responses to ANG II were determined in the presence and absence of the AT 1 receptor antagonist losartan (100 M) or the AT2 receptor antagonist PD-123319 (100 M). The cells were then collected for RNA isolation, and the supernatants were collected for ET-1 ELISA measurement. All animal protocols were approved and conducted according to the recommendations from the Research Sub-Committee of Brock University on Animal Care and Use and the Canadian Council on Animal Care.
Characterization of isolated cells by immunocytochemistry and RT-PCR.
To demonstrate that cultured cells used in our studies were not contaminated by endothelial cells, vascular smooth muscle cells, or leukocytes, we characterized cultured cells for specific cell markers by means of immunocytochemistry and/or RT-PCR. For the immunohistochemical studies, cultured cells were stained with one of following antibodies: anti-human von Willebrand factor (vWF; 1:500, 1 h at room temperature; Sigma) and acetylated low-density lipoprotein 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethyl-indocarbocyanine perchlorate complex (Dil-Ac-LDL; 10 g/ml, 4 h at 37°C; Biochemical Technologies, Stoughton, MA) as markers for endothelial cells; anti-desmin (1:20, 1 h at the room temperature; Sigma), a marker for differentiated vascular smooth muscle cells; and anti-vimentin (1:100, 1 h at room temperature; Sigma), a nonspecific marker for many cell types.
For characterization of cell types in the RT-PCR studies, total RNA was extracted from confluent cultured adventitial cells or from the intact aorta by using Trizol (Molecular Research Center, Cincinnati, OH). For the reverse transcription stage, 1 g of total RNA, treated with DNase I, was reverse transcribed in the presence of a random primer and Moloney murine leukemia virus reverse transcriptase (Perkin Elmer). For the qualitative RT-PCR, the synthesized cDNA was amplified by PCR, using a GeneAmp thermal cycler (Perkin Elmer) with 1.25 units of Taq polymerase (Clontech), 20 mM Tris ⅐ HCl (pH 8.0), 50 mM KCl, 0.2 mM dNTP, 1.5 mM MgCl 2, and 10 pmol/l each of the gene-specific oligonucleotide primers shown in Table 1 . The cyclic program was as follows: initial denaturization at 95°C for 2 min, denaturization at 95°C for 1 min, annealing at 60°C for 1 min, extension at 72°C for 1 min, and a last cycle at 72°C for 5 min. The amplifications were carried out for 30 cycles. PCR products were electrophoresed on 2% agarose gel and stained with ethidium bromide. The amplified DNA from both the adventitial cell cultures and from the aorta were characterized and compared for cell markers of endothelial cells (vWF), vascular smooth muscle cells (myosin heavy chain and desmin), and leukocytes (CD8). The housekeeping gene ␤-actin was used as a positive control.
Cloning and sequencing of mouse preproET-1 cDNA. Total RNA extraction and reverse transcription were similar to the procedures described above. The primer sequences for mouse preproET-1 are listed in Table 2 . For cloning and sequencing of preproET-1 cDNA, the amplification was carried out for 30 cycles (94°C, 30 s; 55°C, 1 min; and 68°C, 1 min). The PCR-amplified open reading frame-containing mouse preproET-1 cDNA was purified and ligated into pCR2.1 cloning vector by using a TA cloning kit (Invitrogen). The construct was transformed and propagated in IN␣FЈ competent cells (Invitrogen) with white/blue selection using ampicillin-selective Luria-Bertani medium. Candidate colonies were selected for confirmation with EcoRI restriction endonuclease (3.89 and 0.64 kb). To further determine the orientation of the inserted preproET-1 cDNA clones, we used ApaI restriction endonuclease to pick up preproET-1/pCR2.1F clones that were reverse-complementary to the strand containing T7 promoter (4.25 and 0.28 kb). The clone was then sequenced bidirectionally with T7 and M13 reverse sequencing primers with an automatic DNA sequencer (ABI 373A; Applied Biosystems) for further confirmation. The confirmed nucleotide sequence of mouse preproET-1 cDNA was deposited into the DDBJ/EMBL/GenBank database (accession no. AB081657).
Qualitative and relative quantification of mRNA of preproET-1, ET A/ETB receptor, and type I procollagen ␣1 by RT-PCR. Total RNA extraction and reverse transcription were similar to the procedures described above. The primer sequences for mouse preproET-1, ET A/ ETB receptor, and type I procollagen ␣1 are listed in Table 2 . For quantification of expression of preproET-1 transcript before and after ANG II treatment, a QuantumRNA ␤-actin internal control was used for relative RT-PCR (Ambion). Briefly, the RT-PCR protocol was similar to the qualitative RT-PCR except for a 2:8 ratio of ␤-actin primers. The competimers mix was added to PCR reactions. The amplification was carried out for 30 cycles (94°C, 30 s; 55°C, 1 min; and 68°C, 1 min). The PCR product was analyzed by electrophoresis with a 1.2% agarose gel and visualized by ethidium bromide staining.
Measurement of ET-1 release by ELISA. The method has been described previously (50) . The concentration of ET-1 in the culture medium was determined using a commercial ELISA kit (ALPCO, Windham, NH). The anti-ET-1 antibody that was used in the kit showed 100% specificity for ET-1 and ET-2, with Ͻ1% crossreactivity to ET-3 and big ET-1. The cellular protein concentration was determined with Bradford reagent (Bio-Rad). The ET-1 release was expressed as femtomoles of ET-1 per milligram of protein.
Measurement of procollagen production by Western blotting.
The cells were cultured with or without different treatments for 24 h and lysed with a lysis buffer containing 50 mM HEPES (pH 7.5), 100 mM NaCl, 1% Triton, 2.5 mM ␤-glycerophosphate, 10% glycerol, 5 mM MgCl 2, 1 mM EGTA, 50 mM NaF, 1 mM sodium orthovanadate, 10 g/ml leupeptin, 10 g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Equal amounts of total proteins (20 g) were electrophoresed in 7% SDS-PAGE under reducing conditions and transferred to a nitrocellulose membrane (Hybond-C; Amersham Pharmacia Biotechnology). The membranes were incubated in the block buffer containing 5% dry milk for 1.5 h. Procollagen type I was detected by incubating the membrane with 1:7,000-diluted polyclonal antibody against procollagen type I (Santa Cruz Biotechnology) overnight at 4°C. After being washed five times, the membranes were incubated with a 1:2,000-diluted secondary peroxidase-conjugated antibody and detected using the ECL detection system (Amersham Pharmacia Biotechnology) according to manufacturer's instructions.
Data analysis. Relative RT-PCR gel images were digitized with an automated digitizing system (UN-SCAN-IT ver. 5; Silk Scientific). Data are expressed as means Ϯ SE. Statistical comparisons were made using ANOVA. Significance was accepted at P Ͻ 0.05.
RESULTS

Characterization of vascular adventitial fibroblasts.
Under the microscope, adventitial fibroblasts derived from the explants displayed a smooth cell border and spindlelike bipolar and tripolar morphology. Each pole presented a small process. After confluence, these cells displayed a multilayer phenotype. Immunocytochemical analysis of cultured cells derived from the adventitia showed no staining for human vWF (Fig. 1A) , Dil-Ac-LDL (Fig. 1B) , and desmin (Fig. 1C) . In contrast, all cells had strong positive staining for vimentin (Fig. 1D) . These results indicate that our cell culture contained primarily fibroblasts with little or no contamination from endothelial and smooth muscle cells. Characterization of mRNA of various cell markers in cultured vascular adventitial cells by RT-PCR is shown in Fig. 2 . Cultured cells derived from the adventitia of the aorta showed no expression for vWF, CD8, myosin heavy chain (vascular smooth muscle cell marker), and desmin (vascular smooth muscle cell marker). In contrast, the aorta had strong positive staining for vWF, CD8, myosin heavy chain, and desmin. Both cultured fibroblasts and aorta tissue expressed ␤-actin.
Cloning and sequencing of mouse ET-1 cDNA. Sequencing of cloned mouse fibroblast preproET-1 cDNA showed that the sequence was 100% identical to a mouse cDNA that was previously found in the GenBank database (accession no. NM_010104). Because this preproET-1 cDNA clone represented a new clone from a new tissue type of mouse that was not reported previously, the sequence of the clone was deposited into the DDBJ/EMBL/GenBank database (accession no. AB081657).
Effect of ANG II on preproET-1 mRNA expression. The effects of incubation time with ANG II on the expression of preproET-1 mRNA in cultured aortic adventitial fibroblasts are presented in Fig. 3 . The expression of preproET-1 mRNA increased within the first 30 min of incubation with ANG II (100 nM) and continued to increase further, reaching a maximum at the 1.5 h mark (P Ͻ 0.05). Thereafter, preproET-1 mRNA expression decreased progressively. After 12 h, expression of preproET-1 mRNA was similar to that observed in the control group (P Ͼ 0.05).
The effects of various concentrations of ANG II on expression of preproET-1 mRNA in cultured aortic adventitial fibroblasts are presented in Fig. 4 . The cells were incubated in the presence and absence of ANG II (10 nM, 100 nM, and 1 M) for 90 min. In the absence of ANG II, preproET-1 mRNA expression was detectable but low. In contrast, addition of ANG II evoked a concentration-dependent increase in preproET-1 mRNA expression. Figure 5 presents the effects of ANG II receptor antagonists on the increase in preproET-1 mRNA expression evoked by ANG II. Pretreatment with the AT 1 receptor antagonist losartan (100 M), but not the AT 2 receptor antagonist PD-123319 (100 M), blocked the elevations in preproET-1 mRNA evoked by ANG II. Neither antagonist affected preproET-1 mRNA expression in the absence of ANG II. These data suggest that the induction was mediated by AT 1 receptors.
Effects of ANG II on ET-1 release. The effects of various concentrations of ANG II on ET-1 peptide levels in culture medium are presented in Fig. 6 . In the absence of ANG II, ET-1 levels in the medium were modest. The addition of ANG II evoked concentration-dependent increases in ET-1. The maximum increase evoked by ANG II was three-to fourfold higher than basal levels. Figure 7 presents the effects of ANG II receptor antagonists on ET-1 release. The ANG II-evoked increases in ET-1 release were blocked by the AT 1 receptor antagonist losartan (100 M) but not by the AT 2 receptor antagonist PD-123319 (100 M). Neither antagonist affected ET-1 levels in the absence of ANG II.
ANG II-evoked increases in expression of type I procollagen ␣1. The expression of type I procollagen ␣1 mRNA in aortic adventitial fibroblasts is presented in Fig. 8 . In the absence of ANG II, expression of type I procollagen ␣1 mRNA was detectable but low. In contrast, incubation with 100 nM ANG II for 24 h evoked a dramatic increase in type I procollagen ␣1 mRNA expression. Strikingly, the increase in type I procollagen ␣1 mRNA expression evoked by ANG II was inhibited by the ET A receptor antagonist BQ-123 but not by the ET B Fig. 2 . Expression of various cell markers and ␤-actin mRNA in cultured vascular adventitial fibroblasts and aorta tissues as determined by RT-PCR. Lane 1, DNA marker; lanes 2 and 3, vWF (endothelial cell marker) and ␤-actin mRNA expression in the cultured vascular fibroblasts and aorta tissue, correspondingly; lanes 4 and 5, CD8 (leukocyte marker) and ␤-actin mRNA expression in the cultured vascular fibroblasts and aorta tissue, correspondingly; lanes 6 and 7, myosin heavy chain (MHC, smooth muscle cell marker) and ␤-actin mRNA expression in the cultured vascular fibroblasts and aorta tissue, correspondingly; and lanes 8 and 9, desmin (smooth muscle cell marker) and ␤-actin mRNA expression in the cultured vascular fibroblasts and aorta tissue, correspondingly. The photograph is a representative example of 3 experiments from 3 mice. receptor antagonist BQ-788. Moreover, the increase in type I procollagen ␣1 mRNA levels evoked by ANG II was inhibited by AT 1 receptor antagonist losartan (100 M) but not by the AT 2 receptor antagonist PD-123319 (100 M).
The protein levels of type I procollagen ␣1 in aortic adventitial fibroblasts are presented in Fig. 9 . The responses of the type I collagen protein parallel the results for procollagen mRNA.
Expression ET A and ET B receptors in adventitial fibroblasts. To test whether ET-1 receptors are present in adventitial fibroblasts, we tested the mRNA of ET A and ET B receptors using RT-PCR. The results show that both ET A and ET B receptors are expressed in aortic adventitial fibroblasts (Fig. 10) .
DISCUSSION
In this study, we have demonstrated for the first time that adventitial fibroblasts synthesize and release ET-1 after stimulation by ANG II (10 nM to 1 M) and that the released ET-1 is biologically active. Five lines of evidence support this conclusion. First, we discovered that ANG II evokes a concentration-and time-dependent increase in preproET-1 mRNA. Thus adventitial cells express the message for ET-1 synthesis, and the expression is responsive to an external stimulus. Second, we also showed for the first time that adventitial fibroblasts release ET-1, the peptide product. Thus we have provided evidence at both the gene expression level and the end-product level for the synthesis and release of ET-1 in response to stimulation by a hormone involved in blood pressure regulation, namely, ANG II. Increases in preproET-1 mRNA were evident within 30 min after ANG II treatment and reached a peak within 1.5 h. Because of the sensitivity of the assay for ET-1, it was not possible to measure the time course of ET-1 release in the medium; rather, it proved necessary to measure the amount of ET-1 accumulated over the 24-h incubation period. This approach seems reasonable, because one would expect the synthesis of the peptide to lag the expression of the message. Third, we cloned and sequenced the preproET-1 cDNA from mouse adventitial fibroblasts. We found that the nucleotide sequence of adventitial preproET-1 cDNA is identical to the cDNA of endothelial cells. Fourth, we demonstrated a potential role of vascular adventitial fibroblastreleased ET-1 in modulating ANG II-induced extracellular matrix production. We found that the ANG II-stimulated type I procollagen ␣1 mRNA expression and protein synthesis were inhibited by the ET A receptor inhibitor BQ-123 but not by the ET B antagonist BQ-788. Fifth, we demonstrated the existence of ET A and ET B receptors in vascular adventitial fibroblasts. These findings are consistent with the notion that ET-1 may contribute to collagen synthesis by stimulating ET A receptors. Collagen is a major component of the extracellular framework of blood vessels, comprising up to 60% of the total protein content (4, 38) . Collagen is produced primarily by fibroblasts, although smooth muscle and endothelial cells may participate. Of the many different types of collagen, type I is the predominant type of collagen found in artery walls. Altogether, the work reported in this article provides strong evidence demonstrating the synthesis and release of ET-1 in response to ANG II, a hormone implicated in some models of hypertension. Moreover, the effects of ANG II-evoked ET-1 release on collagen synthesis suggest a potentially biologically meaningful role for this interaction at the functional level.
The ANG II-evoked increases in ET-1 synthesis and release appear to be mediated by the AT 1 subtype. The AT 1 antagonist losartan, but not the AT 2 antagonist PD-123319, blocked the increase in ET-1 evoked by ANG II. The signal transduction pathways mediating release of ET-1 are complex. The topic has been reviewed by Russell and Davenport (31) . In endothelial cells, there appear to be two distinct secretory pathways, a constitutive pathway involving continuous release and a regulated pathway involving stimulated release. The constitutive pathway is modulated at the level of mRNA transcription, whereas the regulated pathway appears to involve release from storage granules known as Weibel-Palalde bodies. Both reactive oxygen species and Ras-Raf-ERK pathway are required for ET-1-induced ET-1 gene expression in rat cardiac fibroblasts (9, 10). Cheng et al. (9) reported that antioxidant suppressed ET-1-induced ET-1 gene expression. Inhibition of ERK could inhibit transcription of the ET-1 gene. Dominant negative mutant of Ras, Raf, and MEK1 also decreased ET-1 transcription. It is not known whether secretory pathways and Ras-Raf-ERK pathway in adventitial cells parallel those in endothelial cells or rat cardiac fibroblasts. Such studies would be complex and are beyond the scope of the current study. Notwithstanding, the data in this article demonstrate that an AT 1 antagonist blocks both ET-1 release and the increases in preproET-1 mRNA and type I procollagen expression. The blockade of ANG II-evoked procollagen synthesis by both the AT 1 receptor antagonist and the ET A antagonist is consistent with the notion that ANG II evokes release of ET-1 release and that this release is biologically meaningful.
Our data suggest that ET-1 contributes to the biological effects of ANG II, and this is consistent with previous findings. ANG II-induced ET-1 expression has been reported in both rat cardiac fibroblasts (10) and aortic smooth muscle cells (18) . Treatment with ET-1 antagonists in ANG II-infused rats inhibited the elevation of blood pressure and cardiac/resistance vessel hypertrophy (26) . The ET A receptor antagonist BQ-123 and the ET-converting enzyme inhibitor phosphoramidon inhibited vascular contractile responses to ANG II in endothelium intact arterial rings (7, 8) . The mixed ET A /ET B antagonist bosentan decreased blood pressure responses to ANG II in both Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) (3). This effect was greater in the SHR and was due to an effect on total peripheral resistance, not on factors that regulate cardiac output. These findings provide direct evidence, at both hemodynamic and tissue levels, for a contribution of ET-1 to the vascular actions of ANG II. Our data show that adventitial fibroblasts may contribute to this important interaction of ANG II and ET-1.
The role of adventitial fibroblasts in the regulation of vascular smooth muscle function is largely unexplored. Present findings suggest that adventitial cells may play a significant role in the vascular response to injury and hypertension. Some studies have demonstrated that cultured aortic adventitial fibroblasts from SHR have higher proliferative activity compared with the cells from WKY rats (52) . The adventitia is a barrier to nitric oxide in the pulmonary artery (40) . We and others also have demonstrated that the adventitia mediates the oxidative stress associated with the ANG II-infused hypertensive model. In this article, we report a novel function of adventitial fibroblasts, namely, the synthesis and release of ET-1.
In addition to the contribution of adventitial ET-1 in regulation of collagen I release, ANG II-evoked ET-1 release from the adventitia could conceivably contribute to other functions. ANG II may be released from perivascular fat tissues. Perivascular fat tissues have been shown to be a rich source of angiotensinogen (13) . ANG II has been shown to generate reactive oxygen species, especially superoxide anion, from the adventitia. Alternatively, ANG II may promote the production of ET-1, which in turn would contribute to either the contraction of the medial smooth muscle cells or the release of reactive oxygen species (25) .
Adventitial ET-1 could also play a significant role in attracting white cell infiltration. It has been reported that hypertension is in part an inflammatory disorder. C-reactive protein level, a marker of inflammation, is increased in humans with hypertension (37). C-reactive protein level is also a good predictor of subsequent development of hypertension (5) . ET-1 has been shown to increase inflammatory cell infiltration, which caused renal tissue damage in aldosterone-dependent hypertension (44) . In addition, ET-1 has been reported to account for polymorphonuclear leukocyte infiltration in ischemia-reperfusion-induced mucosal dysfunction (27) . Thus, although our data suggest a role for ANG II-evoked ET-1 release in the regulation of the extracellular matrix, other roles for adventitial ET-1 are potentially important.
In conclusion, the results reported in this article demonstrate for the first time that the adventitial fibroblasts, like their neighboring endothelial and smooth muscle cells, synthesize and release ET-1 in response to the stimulation of by ANG II. We also have shown that ANG II-evoked ET-1 release contributes to type I procollagen expression through activation of ET A receptors, suggesting a functional role for ANG II-evoked ET-1 release in the regulation of the extracellular matrix. Finally, the results imply that under certain circumstances when the ANG II system is activated (such as in ANG II-dependent hypertension), ANG II may enhance ET-1 synthesis and release from the vascular adventitia, which conceivably may play an important role in the regulation of vascular function in either a paracrine or autocrine fashion.
